| | | | |
Univariate analysis
|
Multivariate analysis
|
|---|
|
Parameter
| |
N
|
% pCR
|
OR
|
95 % CI
|
P value
|
OR
|
95 % CI
|
P value
|
|---|
|
Clinical T stage
|
cT1/cT2
|
106
|
17.9
|
1
|
Reference
| |
1
|
Reference
| |
| |
cT3/T4
|
73
|
6.8
|
0.34
|
0.12–0.95
|
0.039
|
0.49
|
0.16–1.50
|
0.209
|
|
Clinical N stage
|
cN0
|
84
|
21.4
|
1
|
Reference
| |
1
|
Reference
| |
| |
cN+
|
95
|
6.3
|
0.25
|
0.09–0.66
|
0.005
|
0.19
|
0.06–0.58
|
0.003
|
|
HR status
|
ER+ and/or PR+
|
151
|
8.6
|
1
|
Reference
| |
1
|
Reference
| |
| |
Triple negative
|
28
|
39.3
|
6.87
|
2.66–17.7
|
0.00007
|
9.35
|
3.09–28.3
|
0.00008
|
|
Allocated treatment
|
TAC + ZA
|
87
|
14.9
|
1
|
Reference
|
0.559
| | | |
|
TAC only
|
92
|
12.0
|
0.77
|
0.33–1.83
| | | | |
|
Age
| | | |
0.96
|
0.89–1.09
|
0.186
| | | |
|
BMI
| | | |
0.97
|
0.88–1.08
|
0.581
| | | |
|
rs10735380
|
AA
|
97
|
13.4
|
1
|
Reference
| | | | |
|
IGF1
|
AG
|
66
|
13.6
|
1.02
|
0.41–2.55
|
0.966
| | | |
| |
GG
|
5
|
20.0
|
1.61
|
0.17–15.6
|
0.679
| | | |
|
rs1520220
|
CC
|
111
|
15.3
|
1
|
Reference
| | | | |
|
IGF1
|
CG
|
45
|
13.3
|
0.85
|
0.31–2.32
|
0.752
| | | |
| |
GG
|
11
|
0.0
|
–
|
–
|
–
| | | |
|
rs6220
|
AA
|
88
|
11.4
|
1
|
Reference
| | | | |
|
IGF1
|
AG
|
56
|
16.1
|
1.49
|
0.57–3.94
|
0.418
| | | |
| |
GG
|
17
|
17.6
|
1.67
|
0.41–6.48
|
0.475
| | | |
|
rs2270628
|
CC
|
101
|
11.9
|
1
|
Reference
| | | | |
|
IGFBP3
|
CT
|
45
|
17.8
|
1.60
|
0.61–4.24
|
0.342
| | | |
| |
TT
|
9
|
0.0
|
–
|
–
|
–
| | | |
|
rs2854746
|
GG
|
55
|
7.3
|
1
|
Reference
| |
1
|
Reference
| |
|
IGFBP3
|
GC
|
72
|
16.7
|
2.55
|
0.78–8.40
|
0.124
|
3.06
|
0.82–11.4
|
0.097
|
| |
CC
|
33
|
21.2
|
3.43
|
0.92–12.8
|
0.066
|
4.02
|
0.92–17.6
|
0.065
|
| |
GG
|
55
|
7.3
|
1
|
Reference
| |
1
|
Reference
| |
| |
GC/CC
|
105
|
18.1
|
2.82
|
0.91–8.74
|
0.073
|
3.35
|
0.96–11.7
|
0.058
|
|
rs4320932
|
TT
|
106
|
15.1
|
1
|
Reference
| | | | |
|
IGF2
|
TC
|
57
|
12.3
|
0.79
|
0.30–2.04
|
0.623
| | | |
| |
CC
|
8
|
12.5
|
0.80
|
0.09–6.98
|
0.843
| | | |
|
rs2016347
|
GG
|
45
|
4.4
|
1
|
Reference
| |
1
|
Reference
| |
|
IGF1R
|
GT
|
94
|
17.0
|
4.41
|
0.97–20.1
|
0.055
|
5.58
|
1.08–28.7
|
0.040
|
| |
TT
|
32
|
15.6
|
3.98
|
0.72–22.0
|
0.113
|
6.67
|
1.03–43.1
|
0.046
|
| |
GG
|
45
|
4.4
|
1
|
Reference
| |
1
|
Reference
| |
| |
GT/TT
|
126
|
16.7
|
4.30
|
1.00–19.1
|
0.056
|
5.82
|
1.17–29.1
|
0.032
|
-
BMI body mass index, CI confidence interval, ER estrogen receptor, HR hormone receptor, IGF insulin-like growth factor 1, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor 1 receptor, OR odds ratio, pCR pathological complete response, PR progesterone receptor, SNP single nucleotide polymorphism, TAC docetaxel, doxorubicin, cyclophosphamide, ZA zoledronic acid
